Biochemical recurrence develops in almost one-third of men with prostate cancer after treatment with prostatectomy or radiation therapy for localized prostate cancer. It often occurs early on in the course of prostate cancer and indicates the cancer might be coming back. Because of this, it has be...
Adalimumab is an anti-TNF-alpha drug widely used for the treatment of both psoriasis and PsA. Controlled clinical trials demonstrated that adalimumab is characterized by a high degree of clinical response. The aim of this review is to report the safety, efficacy, and recent findings in the ...
decreasing = TRUE) } # Current implementation potential_interactions(shp, v = "PSA") #> GLEASON DPROS VOL DCAPS RACE AGE #> 0.14827267 0.10383619 0.07988404 0.07166984 0.06715848 0.05922560 # Suggested implementation potential
But after adjusting for other factors, these associations were no longer statistically significant. Patients with elevated PSA and high Gleason scores were less likely to receive radical prostatectomy even after the adjustment. From 1997 to 2001, utilization of radiation and hormonal therapies increased,...
This study aims to develop an approach to treat the human and organizational factors for a multi-unit HRA on the basis of Standardized Plant Analysis Risk HRA (SPAR-H) method. This approach is applicable to level 1, 2, and 3 PSA. Firstly, six multi-unit task types were considered based...
Estimates the cost-effectiveness of combined levamisole and fluorouracil as adjuvant treatment for patients with stage three colon cancer. Calculations on the cost of treatment; Negligible effect of quality-of-life adjustments on the cost-effectiveness outcome; Recommendation for adjuvant therapy as a cos...
Hormonal Blockade salvage treatment of PSA only recurrently prostate cancer after interstitial High Dose Rate (HDR) brachytherapy for early stage prostate cancer: Long-term follow-up in 26 patientsdoi:10.1016/j.brachy.2010.02.177Rufus J. Mark
In a case series of 23 patients with MSI-H/ dMMR mCRPC, 11 patients were treated with anti-PD-1/PD-L1 therapy and 6 patients (54.4%) achieved a ≥ 50% PSA decline. Radiographic responses occurred in 4 out of these 6 patients, and 5 patients were still on therapy for as long...
Nanobodies: a tool to open new horizons in diagnosis and treatment of prostate cancerNanobodyVHHProstate cancerPSMAPSAProstate cancer is one of the most ... M Hosseindokht,H Bakherad,H Zare - 《Cancer Cell International》 被引量: 0发表: 2021年 prostate cancer new horizons in research and...
The posttreatment prostate-specific antigen (PSA) profile can often be difficult to interpret after external beam radiotherapy for prostate cancer. We performed an extensive analysis of post-radiotherapy PSA measurements to determine the clinical significance of biochemical failure (BF) and the correlation...